Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus

Journal of Molecular Graphics and Modelling

Volumn 22, Issue 3, 2004, Pages 209-220

  Frecer, Vladimír ^a,b   Kabeláč, Martin ^a,d   De Nardi, Piergiuseppe ^c   Pricl, Sabrina ^c   Miertuš, Stanislav ^a  

^a Intl Ctr Sci High Technol   (Italy)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c UNIVERSITY OF TRIESTE   (Italy)

^d J HEYROVSKÝ INSTITUTE OF PHYSICAL CHEMISTRY   (Czech Republic)

Author keywords

Combinatorial optimisation; Hepatitis C virus; Molecular modelling; NS3 serine protease; Peptidic inhibitors; Structure based molecular design

Indexed keywords

AMINO ACIDS; CARBOXYLIC ACIDS; MOLECULAR STRUCTURE; VIRUSES;

BINDING POCKETS;

ENZYMES;

AMINO ACID; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; CATALYSIS; DRUG DESIGN; ENZYME ACTIVITY; ENZYME BINDING; HEPATITIS C VIRUS; MOLECULAR DYNAMICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SOLVATION;

HEPATITIS C VIRUS;

EID: 84962396688     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1093-3263(03)00161-X     Document Type: Article

References (45)

1. M. Houghton, Hepatitis C viruses, in: B.N. Fields, D.M. Knipe, P.M. Howley (Eds.), Fields' Virology, third ed., Lippincott-Raven, Philadelphia, PA, 1996, pp. 1035-1058.
2. Avital J., Hepatitis C. Curr. Opin. Infect. Dis. 11:1998;293-299.
3. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:1997;347-356.
4. Hoofnagle J.H. Therapy for acute hepatitis C. N. Engl. J. Med. 345:2001;1495-1497.
5. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. Characterization of the hepatitis C virus-encoded serine protease: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67:1993;2832-2843.
6. Lesk A., Fordham W.D. Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J. Mol. Biol. 258:1996;501-537.
7. Neddermann P., Tomei L., Steinkühler C., Gallinari P., Tramontano A., De Francesco R. The non-structural proteins of the hepatitis C virus: structure and function. Biol. Chem. 378:1997;469-476.
8. Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N., Moomaw E.W., Adachi T., Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 87:1996;331-342.
9. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., Chambers S.P., Markland W., Lepre C.A., O'Malley E.T., Harbeson S.L., Rice C.M., Murcko M.A., Caron P.R., Thomson J.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 87:1996;343-355. PDB entry code 1A1R.
10. Cicero D.O., Barbato G., Koch U., Ingallinella P., Bianchi E., Nardi M.C., Steinkühler C., Cortese R., Matassa V.G., De Francesco R., Pessi A., Bazzo R. Structural characterization of the interactions of optimised product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J. Mol. Biol. 289:1999;385-396.
11. Barbato G., Cicero D.O., Cordier F., Narjes F., Gerlach B., Sambucini S., Grzesiek S., Matassa V.G., De Francesco R., Bazzo R. Inhibitor binding induces active site stabilisation of the HCV NS3 protein serine protease domain. EMBO J. 19:2000;1195-1206.
12. I. Schecter, A. Berger, On the size of the active site in proteases, Biochem. Biophys. Res. Commun. 27 (1967) 157-162.
13. Zhang R., Durkin J., Windsor W.T., McNemar C., Ramanathan L., Le H.V. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J. Virol. 71:1997;6208-6213.
14. Fattori D., Urbani A., Brunetti M., Ingenito R., Passi A., Prendergast K., Narjes F., Matassa V.G., De Francesco R., Steinkühler C. Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer. J. Biol. Chem. 275:2000;15106-15113.
15. Ingallinella P., Altamura S., Bianci E., Taliani M., Ingenito R., Cortese R., De Francesco R., Steinkühler C., Pessi A. Potent peptide inhibitors of human hepatitis C virus protease are obtained by optimising the cleavage products. Biochemistry. 37:1998;8906-8914.
16. Steinkühler C., Urbani A., Tomei L., Biasol G., Sardana M., Bianchi E., Pessi A., De Francesco R. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J. Virol. 70:1996;6694-6700.
17. Urbani A., Bianchi E., Narjes F., Tramontano A., De Francesco R., Steinkühler C., Pessi A. Substrate specificity of the hepatitis C virus serine protease NS3. J. Biol. Chem. 272:1997;9204-9209.
18. LaPlante S.R., Cameron D.R., Aubry N., Lefebvre S., Kukolj G., Maurice R., Thibeault D., Lamarre D., Llinàs-Brunet M. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem. 274:1999;18618-18624.
19. Steinkühler C., Biasiol G., Brunetti M., Urbani A., Koch U., Cortese R., Passi A., De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry. 37:1998;8899-8905.
20. Ingallinella P., Bianci E., Ingenito R., Koch U., Steinkühler C., Altamura S., Pessi A. Optimisation of the P′-region of peptide inhibitors of Hepatitis C virus NS3/4A protease. Biochemistry. 39:2000;12898-12906.
21. Llinàs-Brunet M., Bailey M., Deziel R., Fazal G., Gorys V., Goulet S., Halmos T., Maurice R., Poirier M., Poupart M.-A., Rancourt J., Thibeault D., Wernic D., Lamarre D. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8:1998;2719-2724.
22. Llinàs-Brunet M., Bailey M., Fazal G., Ghiro E., Gorys V., Goulet S., Halmos T., Maurice R., Poirier M., Poupart M.-A., Rancourt J., Thibeault D., Wernic D., Lamarre D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10:2000;2267-2270.
23. Johansson A., Hubatsch I., Åkerblom E., Lindeberg G., Winiwarter S., Danielson U.H., Hallberg A. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg. Med. Chem. Lett. 11:2001;203-206.
24. Dundson R.M., Greening J.R., Jones P.S., Jordan S., Wilson F.X. Solidphase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 protease. Bioorg. Med. Chem. Lett. 10:2000;1577-1579.
25. Narjes F., Brunetti M., Coalrusso S., Gerlach B., Koch U., Biasiol G., Fattori D., De Francesco R., Matassa V.G., Steinkühler C. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry. 39:2000;1849-1861.
26. Cassidy C.S., Lin J., Frey P.A. A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. Biochemistry. 36:1997;4576-4584.
27. Sudo K., Matsumoto Y., Matsushima M., Fujiwara M., Konno K., Shimotohno K., Shigeta S., Yokota T. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem. Biophys. Res. Commun. 18:1997;643-647.
28. Sing W.T., Lee C.L., Yeo S.L., Lim S.P., Sim M.M. Arylalkylidene rhodamine with bulky and hydrophobic functional groups as selective HCV NS3 protease inhibitor. Bioorg. Med. Chem. Lett. 11:2001;91-94.
29. 2+-dependent inhibitor of HCV NS3 serine protease. Bioorg. Med. Chem. Lett. 11:2001;2355-2359.
30. Di Marco S., Rizzi M., Volpari C., Walsh M.A., Narjes F., Colarusso S., De Francesco R., Matassa V.G., Sollazzo M. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 275:2000;7152-7157. (PDB entry codes 1DY8 and 1DY9).
31. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 28:2000;235-242. ( http://www.pdb.org/ ).
32. Insight II 2000 and Discover 2.98 Molecular Modelling Software, 2000, Accelrys Inc., San Diego, CA.
33. Maple J.R., Hwang M.-J., Stockfish T.P., Dinur U., Waldman M., Ewing C.S., Hagler A.T. Derivation of class II force fields. 1. Methodology and quantum force field for the alkyl functional group and alkane molecules. J. Comput. Chem. 15:1994;162-182.
34. Frecer V., Miertus S. Interactions of ligands with macromolecules: rational design of specific inhibitors of aspartic protease of HIV-1. Macromol. Chem. Phys. 203:2002;1650-1657.
35. Bashford D., Case D.A. Generalized Born models of macromolecular solvation effects. Annu. Rev. Phys. Chem. 51:2000;129-152.
36. Tomasi J., Persico M. Molecular interactions in solutions: an overview of methods based on continuous distribution of the solvent. Chem. Rev. 94:1994;2027-2094.
37. Miertus S., Scrocco E., Tomasi J. Electrostatic interaction of a solute with a continuum. A direct utilization of ab initio molecular potentials for the prevision of solvent effects. Chem. Phys. 55:1981;117-129.
38. Frecer V., Miertus S. Polarizable continuum model of solvation for biopolymers. Int. J. Quant. Chem. 42:1992;1449-1468.
39. Thole B.T. Molecular polarizabilities calculated with a modified dipole interaction. Chem. Phys. 59:1981;341-350.
40. Frecer V., Ho B., Ding J.L. Interpretation of biological activity data of bacterial endotoxins by simple molecular models of mechanism of action. Eur. J. Biochem. 267:2000;837-852.
41. Koch U., Biasol G., Brunetti M., Fattori D., Pallaoro M., Steinkühler C. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilisation. Biochemistry. 40:2001;631-640.
42. Burley S.K., Petsko G.A. Weakly polar interactions in proteins. Adv. Protein. Chem. 39:1988;125-189.
43. Markley J.L., Westler W. Protonation state dependence of hydrogen bond strengths and exchange rates in a serine protease catalytic triad: bovine chymotrypsinogen. Biochemistry. 35:1996;11092-11097.
44. Navia M.A., McKeever B.M., Springer J.P., Lin T.Y., Williams H.R., Fluder E.M., Dorn C.P., Hoogsteen K. Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84 Å resolution. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7-12.
45. Ingallinella P., Fattori D., Altamura S., Steinkühler C., Koch U., Cicero D.O., Bazzo R., Cortese R., Bianchi E., Pessi A. Prime site binding inhibitors of serine protease: NS3/4A of hepatitis C virus. Biochemistry. 41:2002;5483-5492.